3D‐Quantitative Structure–Activity Relationship Studies on Benzothiadiazepine Hydroxamates as Inhibitors of Tumor Necrosis Factor‐α Converting Enzyme
暂无分享,去创建一个
[1] G R Marshall,et al. 3D-QSAR: a current perspective. , 1995, Trends in pharmacological sciences.
[2] J. Buolamwini,et al. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. , 2002, Journal of medicinal chemistry.
[3] P. Reinemer,et al. The metzincins — Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zinc‐peptidases , 1995, Protein science : a publication of the Protein Society.
[4] R. Giridhar,et al. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors. , 2006, Acta pharmaceutica.
[5] Sujit Roy,et al. 3-D QSAR studies on new dibenzyltin(IV) anticancer agents by comparative molecular field analysis (CoMFA). , 2002, Bioorganic & medicinal chemistry letters.
[6] Johann Gasteiger,et al. Multivariate structure‐activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method , 1984 .
[7] S. Wold,et al. The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .
[8] Kurt Varmuza,et al. Multivariate Data Analysis in Chemistry , 2008 .
[9] S. Mandlekar,et al. Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors , 2003 .
[10] D. E. Patterson,et al. Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .
[11] Xiaomin Luo,et al. Molecular docking and 3D-QSAR studies on gag peptide analogue inhibitors interacting with human cyclophilin A. , 2002, Journal of Medicinal Chemistry.
[12] D. Ferguson,et al. QSAR and CoMFA: a perspective on the practical application to drug discovery. , 2000, Drug design and discovery.
[13] R. Giridhar,et al. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA. , 2006, European journal of medicinal chemistry.
[14] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[15] R. Black. Tumor necrosis factor-alpha converting enzyme. , 2002, The international journal of biochemistry & cell biology.
[16] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[17] A Tropsha,et al. Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. , 1995, Journal of medicinal chemistry.
[18] N. Hooper,et al. Families of zinc metalloproteases , 1994, FEBS letters.
[19] H. Kubinyi. Comparative Molecular Field Analysis (CoMFA) , 2002 .
[20] B. Jaffee,et al. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release. , 2001, Journal of Medicinal Chemistry.
[21] Eamonn F. Healy,et al. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .
[22] Bing Xiong,et al. Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses. , 2002, Journal of medicinal chemistry.
[23] Wolfgang Sippl,et al. Receptor-based 3D QSAR analysis of estrogen receptor ligands – merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods , 2000, J. Comput. Aided Mol. Des..
[24] R. Giridhar,et al. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach. , 2006, Bioorganic & medicinal chemistry letters.
[25] W. Welsh,et al. Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: applying a "divide and conquer" strategy. , 2001, Journal of medicinal chemistry.
[26] W A Buurman,et al. Tumor necrosis factor: function, release and clearance. , 1996, Critical reviews in immunology.
[27] R. Giridhar,et al. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. , 2008, European journal of medicinal chemistry.
[28] E. Eisenstein,et al. Ligand binding-promoted conformational changes in yeast ornithine transcarbamoylase. , 1986, The Journal of biological chemistry.
[29] J. Sufrin,et al. Steric mapping of the L-methionine binding site of ATP:L-methionine S-adenosyltransferase. , 1981, Molecular pharmacology.
[30] Matthew Clark,et al. Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases , 1990 .
[31] H. Berendsen,et al. Computer simulation of the dynamics of hydrated protein crystals and its comparison with x-ray data. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[32] James J. P. Stewart,et al. MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..